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Chapter 6
MMP Activity Detection in Zymograms
Péter Bencsik, Monika Bartekova, Anikó Görbe, Krisztina Kiss, 
János Pálóczi, Jana Radosinska, Gergő Szűcs, and Péter Ferdinandy
Abstract
Matrix metalloproteinases (MMP) belong to a distinguished class of zinc-dependent endopeptidases. 
Zymography is a semi-quantitative tool for determining the activity of different MMP isoenzymes in a 
variety of biological samples. In substrate gel zymography, protein samples of different origin (tissue, cell 
lysates, plasma/serum, perfusates, other liquids) are separated in sodium dodecyl sulfate (SDS) polyacryl-
amide gels containing copolymerized substrate (gelatin, casein, elastin, etc.), and after incubation-enabling 
substrate cleavage by MMPs, MMP activities are detected after the gel staining as transparent bands against 
a dark-blue background. In situ zymography is a histological modification of substrate zymography in 
frozen sections, allowing detection of the localization of the MMP activities within the tissue. Here, we 
describe detailed experimental protocols of all abovementioned techniques and provide examples for 
 several sample measurements.
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1 Introduction
Matrix metalloproteinases (MMPs) are enzymes that belong to the 
family of zinc-dependent endopeptidases and are known to play a 
crucial role in the dynamic processing of the extracellular matrix 
(ECM) facilitating the degradation of matrix material. On the other 
hand, MMPs have been also shown to be present intracellularly, 
thereby influencing physiological as well as pathological intracellular 
signal transduction processes and the contractile machinery. 
Therefore, MMPs are interesting drug targets for several pathologies 
(see for a review: [1]). The family of MMPs include close to 30 mem-
bers (see for reviews: [2, 3]); many of them shown to be activated due 
to different physiological as well as pathological  situations in different 
tissues. Some of the important family members together with their 
characteristic features are shown in Table 1. MMPs are synthesized as 
zymogens and can be activated by proteolytic cleavage of an amino-
terminal domain, by oxidative/nitrosative- induced conformational 
1.1 Matrix 
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Table 1 
The family of MMPs and their characteristic features
MMP 
codes Alternative names
Molecular weight 
(kDa)
Substrates PathologiesZa Aa
MMP-1 Interstitial 
collagenase
57 52 Gelatin Atherosclerosis, 
melanoma, heart 
failure
MMP-2 Gelatinase A,  
type IV collagenase
75/72 64 Gelatin, elastin Myocardial infarction, 
heart failure, gastritis, 
rheumatoid arthritis
MMP-3 Stromelysin-1 57 45 Gelatin, elastin, 
casein
Brain injury, 
neurodegeneration
MMP-7 Matrilysin 28 19 Gelatin, elastin, 
casein
Tumor-induced 
osteolysis, colon 
cancer
MMP-8 Neutrophil 
collagenase
75 57 Gelatin Coronary artery disease, 
angina
MMP-9 Gelatinase B 92 86 Gelatin, elastin Myocarditis and 
subsequent dilated 
cardiomyopathy, 
ulcerative colitis
MMP-10 Stromelysin-2 57 44 Gelatin, elastin, 
casein
Lung cancer
MMP-11 Stromelysin-3 51 44 Gelatin, elastin, 
casein
Tumor progression, 
breast carcinomas
MMP-12 Macrophage 
metalloelastase
54 22 Gelatin, elastin, 
casein
Granulomatous skin 
diseases, 
inflammatory 
disorders
MMP-13 Collagenase-3 65 48 Gelatin Breast carcinomas
MMP-14 MT1-MMP 66 54 Gelatin, casein Tumor growth by 
activating MMP-2
MMP-15 MT2-MMP 76 N/A Fibronectin 
Laminin
Obesity, preeclampsia, 
ovarian carcinoma
MMP-16 MT3-MMP 64 52/30 Gelatin, casein Breast cancer
MMP-17 MT4-MMP 71 67 N/A Preeclampsia
MMP-19 RASI-1 57 N/A Gelatin Rheumatoid arthritis
MMP-20 Enamelysin 54 42.5 Amelogenesis 
imperfecta
(continued)
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change (without a change in molecular weight), or by phosphoryla-
tion [2, 4]. Activities of MMPs are tightly regulated by their endog-
enous tissue inhibitors (TIMPs) [5].
MMPs play an important role in many physiological and patho-
logical processes, including embryogenesis, wound healing, inflam-
mation, cardiovascular diseases, and tumor development or 
progression [2, 6]. Increased activities of different MMPs have been 
reported to be connected with different pathological situations such 
as ischemia-reperfusion injury [7], myocardial contractile dysfunc-
tion [8], heart failure [9], arthritis [10], neurodegenerative disor-
ders [11], cancer invasion and metastasis [12], liver cirrhosis [13], 
fibrotic lung disease [14], periodontal disease [15] as well as with 
responses to some invasive interventions like anthracycline treat-
ment [16, 17] or chest irradiation [18] used in the cancer therapy. 
On the other hand, inhibition of MMP activities has been shown to 
be connected with some kinds of tissue protection such as ischemic 
preconditioning [19, 20] or flavonoid- induced cardioprotection 
[17]. Moreover, pharmacological inhibition of MMP activities has 
been shown to be cardioprotective in animal models of acute myo-
cardial infarction [21, 22] and has also been shown to be altered in 
coronary artery disease patients [23]. Being able to detect MMPs at 
early stages of the disease is opening a perspective to use MMPs as 
diagnostic markers. MMPs have been well-investigated in clinical 
studies of cardiovascular diseases: MMP-2 and -9 in Chagas cardio-
myopathy [24] and MMP-9 in ST-segment elevation myocardial 
infarction [25]. Protein expression and activation of MMP-2 and 
MMP-9 has clinical relevance and prognostic value in patients with 
colorectal cancer [26]. Fecal MMP-9 is a useful tool for the differen-
tial diagnosis of diarrheic disorders and in the noninvasive evaluation 
of disease activity and mucosal healing in ulcerative colitis [27].
Table 1
(continued)
MMP 
codes Alternative names
Molecular weight 
(kDa)
Substrates PathologiesZa Aa
MMP-21 N/A N/A N/A N/A Melanoma, ovarian and 
colon carcinomas
MMP-22 N/A N/A 42 N/A N/A
MMP-23 N/A N/A N/A N/A Breast cancer
MMP-24 MT5-MMP N/A N/A N/A Brain tumors
MMP-25 MT6-MMP, 
leucolysin
56 38 pro-MMP-2 Inflammatory 
hyperalgesia
MMP-26 Endometase 29 19 Gelatin Lung cancer
aZ and A indicates the zymogen or active form(s) of MMPs, respectively
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Regarding the abovementioned facts, determination of MMP 
activities belongs to very useful methodologies in biomedical 
research and is of high clinical importance since it seems to be a 
powerful diagnostic and/or therapeutic tool for the detection or 
follow-up of the abovementioned pathologies.
MMP activities can be determined by zymography in different 
kinds of biological samples such as heart, brain, liver, lung tissues, 
blood vessels, or in isolated or cultured cell lineages (see Figs. 1, 2, 
and 3). Zymography can be performed as a substrate zymography, 
in which the substrate of the certain MMP is incorporated, copo-
lymerized in a sodium dodecyl sulfate (SDS) polyacrylamide gel, 
and MMPs are separated according to their molecular weights. 
1.2 MMP Activity 
Detection in Biological 
Samples
Fig. 1 Representative gelatin zymograms performed from human samples. 
(Panel A) Human serum samples from patients with coronary artery disease. 
Some of the patients have increased MMP-2 and/or MMP-9 activity as indicated 
by the zymographic intensity at 72 or 86 kDa, respectively. (Panel B) Gelatin 
zymogram from human isolated lymphocytes. 72 kDa MMP-2 activity is mark-
edly visible; however, other activities at 64 kDa (MMP-2) and at 86 kDa (MMP-9) 
can also be observed. Weak gelatinolytic activity signals can be seen in both 
panels at 192 kDa, which may indicate the dimerized form of MMP-9 [28]
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The activity of MMPs is detected by the absence of gelatin in the 
gel, which can be visualized by transilluminating the gel. The activ-
ity of the certain MMP is proportional with the intensity and the 
thickness of the corresponding band on zymogram, which can be 
evaluated electronically by using different software after scanning 
the gels.
Fig. 2 Representative gelatin zymograms performed from homogenates of 
murine tissues (L1–4: lanes 1–4; 15 μg protein was loaded into each wells). 
Panel A represents mouse heart homogenates, which expresses mainly the 
72 kDa isoform of MMP-2. Weak signal for MMP-9 can be observed; however, it 
indicates inappropriate removal of blood from heart samples. (Panel B) Lung 
samples from mice subjected to chronic tobacco smoking (L2 and 4) and their 
controls (L1 and 3). A markedly increased intensity can be observed at 92 kDa 
(MMP-9). (Panel C) Samples derived from the aorta of transgenic mice. L1 and 2: 
ApoB100LDL−/− mice, control and Chlamydia pneumoniae (Cpn) infected; L3 
and 4: ApoE−/−, control and Cpn infected
MMP Activity Detection in Zymograms
Fig. 3 Examples of MMP zymography in isolated and/or cultured cells. (Panel A) Gelatin zymogram from cultured 
neonatal cardiac myocytes after resuspension. Gelatinolytic activities can be detected at completely different 
molecular weights than that of heart homogenates (for comparison see Fig. 2a). (Panel B, C) In situ gelatin 
zymography in fixed neonatal cardiac myocyte culture in normoxic conditions (Panel B) and subjected to simu-
lated ischemia/reoxygeation (Panel C). Panel C shows an increased gelatinolytic activity (represented as green 
fluorescence—DQ™ fluorescent gelatin; red fluorescence: MMP-2 immunostaining by rhodamine-labeled goat 
anti-mouse antibody, blue fluorescence: cell nuclei by Hoechst 33342 staining) in cardiac myocytes, which 
indicates the presence and activation of MMP-2 during simulated ischemic stress. Scale bars = 20 μm
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For the detection of MMP activity in situ in different cell or 
tissue cultures, in situ zymography is a suitable method (Fig. 3). In 
in vivo systems, natural inhibitors of MMPs (tissue inhibitors of 
MMPs, TIMPs) are presented [29]. Therefore, when a study is 
designed for detecting MMPs activity in a certain physiological or 
pathological condition, one should calculate not only with the acti-
vation, but the inhibition of MMPs by TIMPs as well. For this 
reason, reverse zymography has been developed, which allows 
detection of TIMPs activities in gel zymograms. However, this 
chapter is limited for showing the opportunities to detect MMP 
activities in biological samples, thus here we do not provide detailed 
description on the available techniques for detecting TIMPs activ-
ity (for TIMP measurements, see for review [30]).
MMPs cleave different substrates; therefore, the substrate, which is 
copolymerized in the gel, should be determined according to the 
MMP isoform.
Gelatin zymography is predominantly used for measurements 
of activities of MMP-2 and MMP-9 as these two MMPs exert 
strong ability to cleave gelatin as a substrate and are commonly 
called “gelatinases.”
In casein zymography, casein is copolymerized into the poly-
acrylamide gel as a substrate for MMP cleavage. Casein zymogra-
phy is used for estimation of proteolytic activity of MMP-7 due to 
its ability to cleave casein.
The most rarely applied type of zymography is elastin zymog-
raphy, in which soluble elastin is copolymerized in the gel and, 
beside the activity of elastases, it can suitably show elastinolytic 
activity for such MMPs, which cleave basically other substrates like 
gelatin (e.g., MMP-2).
2 Materials
 1. For pulverized tissue samples: Homogenization buffer: 500 mL 
double distilled water (ddH2O), 0.335 g (50 mM) Tris base, 
1 mL (0.5%) Triton X-100. In 500 mL beaker dissolve com-
pounds in 500 mL ddH2O. Adjust to pH 7.4 with 1 M HCl. 
Aliquot into 15 mL Falcon tubes. Store at −20 °C for 1 year. 
Homogenator: Pellet Pestle Motor, Centrifuge (e.g., Hettich 
Universal 320R), BCA Protein Assay Kit for protein 
measurement.
 2. For organ perfusates: Concentrating tubes: Amicon Ultra-4 
30 kDa centrifugal filter unit with Ultracel-30 membrane for 
perfusate concentration.
 3. For cell culture lysates: Phosphate Buffered Saline tablets (PBS): 
In 200 mL beaker dissolve 1 PBS tablet in 100 mL ddH2O. Adjust 
1.3 Types 
of Zymography 
Substrates
2.1 Sample 
Preparation
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to pH 7.2 with 1 mM NaOH prepared freshly; Homogenization 
buffer (see above item 1); Amicon Ultra 10 kDa concentrating 
tubes. Centrifuge (e.g., Hettich Universal 320R)
 1. 30% Acrylamide/0.8% Bisacrylamide, Store: at +4 °C for 
1 year.
 2. Separating Gel Solution—1.5 M Tris–HCl, pH 8.8, Store at 
+4 °C for 1 year.
 3. 2% Gelatin Solution: 100 mg gelatin (type A, from porcine 
skin; stored between 20–25 °C) dissolved in 4.5 mL ddH2O.
 4. 10% (w/v) SDS (sodium dodecyl sulfate) solution. Weigh 10 g 
SDS and dissolve in 100 mL ddH2O (Storage between 
20–25 °C for 1 year).
 5. 10% (w/v) ammonium persulfate (APS) solution: Dissolve 
100 mg of APS in 1 mL ddH2O. Storage: at +4 °C for 1 month
 6. TEMED. Storage: at +4 °C for 1 year.
 7. Stacking Gel Solution: 0.5 M Tris–HCl/SDS, pH 6.8. Storage: 
at +4 °C for 1 year.
 8. ELFO Buffer (25 mM Tris–HCl, 192 mM glycine, 0.1% SDS, 
pH 8.3). Storage: at +4 °C for 1 year. Or self-prepared: 28.83 g 
glycine, 6.0 g Tris base, 2.0 g SDS. Dissolve Tris base and gly-
cine in 1000 mL of ddH2O. Bring solution to 1950 mL with 
ddH2O. Add SDS. Bring solution to 2000 mL total volume 
with ddH2O. Storage: at 4 °C for 1 year.
 9. Non-reducing loading (sample) buffers: use commercial 
“Blue” Zymogram Sample Buffer or commercial “Pink” non- 
reducing lane marker.
 10. For positive control, use “zymography standard,” containing a 
mixture of purified and activated MMP-2 and MMP-9; or 
MMP-2 standard for gelatin and elastin zymography (Fig. 1a). 
For casein zymography, human, recombinant active MMP-7 
can be used.
 11. Renaturation buffer: Renaturation buffer (Bio-Rad). Store: at 
+4 °C for 1 year. Add 1× mL Renaturation buffer (Bio- 
Rad) + 9× mL ddH2O. Storage: prepare freshly.
 12. Development buffer: Development buffer (Bio-Rad) Storage: 
at +4 °C for 1 year. Add 1× mL Development buffer + 9× mL 
ddH2O. Storage: prepare freshly.
 13. For negative control, use 10 mM ethylene glycol tetraacetic 
acid (EGTA, binds Ca2+ ions, which is obligatory for activity of 
MMPs). Dissolve 381 mg EGTA in 90 mL ddH2O + 10 mL 
development buffer.
 14. Coomassie Brilliant Blue (0.05%): 250 mg Coomassie Brilliant 
Blue G-250, 125 mL methanol, 50 mL glacial acetic acid, 
2.2 Gelatin 
Zymography
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325 mL ddH2O. Dissolve 250 mg Coomassie Brilliant Blue in 
the mixture of 125 mL methanol and 50 mL glacial acetic acid 
and dilute it by adding 325 mL ddH2O. Storage: between 
20–25 °C.
 15. Destaining solution: 40 mL methanol, 80 mL acetic acid, 
880 mL ddH2O. Storage: between 20–25 °C
All materials and procedures are identical with gelatin zymography 
except gelatin solution, which is substituted with casein.
 1. Casein solution: 100 mg casein (storage: between 20–25 °C) 
dissolved in 4.5 mL phosphate buffer.
 2. Phosphate buffer (126 mM).
All materials and procedures are identical with gelatin zymography 
except gelatin solution, which is substituted with elastin.
 1. Elastin solution: 54 mg soluble elastin from bovine neck liga-
ment dissolved in 4.5 mL ddH2O.
 1. Gelatin solution: Add 100 mg gelatin to 4.5 mL ddH2O. Gently 
heat and mix solution until it dissolves (beaker will be warm to 
touch, max. 40 °C). If it has cooled down, add 0.5 mL 10% 
(w/v) SDS aqueous solution to reach final desired volume and 
concentration. Prepare freshly (see Note 1).
 2. Casein solution: Dissolve 100 mg casein in 4.5 mL phosphate 
buffer. Stir until casein dissolves. Preparation of phosphate 
buffer: mix 7.12 g Na2HPO4 dissolved in 400 mL ddH2O and 
1.56 g NaH2PO4 dissolved in 100 mL ddH2O, set at pH 7.4. 
Add 0.5 mL 10% w/v SDS aqueous solution to reach final 
desired volume. Alternatively, dissolve 30 mg casein in 2 mL of 
75 mM Tris–HCl, pH 8.8.
 3. Elastin solution: Add 54 mg κ-elastin to 4.5 mL ddH2O. Stir 
until elastin dissolves. Add 0.5 mL 10% w/v SDS aqueous 
solution to reach final desired volume.
The EnzCheck Gelatinase/Collagenase Assay Kit from Invitrogen 
was used. This assay includes the following reagents:
 1. DQ gelatine from pig skin: five vials (1 mg DQ substrate 
lyophilized from 1 mL of PBS in each vial).
 2. 10× Reaction buffer: 50 mL.
 3. 1,10-phenanthroline monohydrate: 30 mg powder in a vial.
 4. Collagenase type IV from Clostridium histolyticum: 500 U col-
lagenase powder in a vial.
2.3 Casein 
Zymography
2.4 Elastin 
Zymography
2.5 Preparation 
of Substrate 
for Electrophoresis
2.6 In Situ 
Zymography
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3 Methods
 1. Weigh out 30–50 mg heart (lung, pancreas, aorta, spleen) tis-
sue powder into a liquid-nitrogen-frozen 1.5 mL Eppendorf 
tube. Avoid thawing. It can be stored at −80 °C for 2 years.
 2. Thaw an appropriate amount of homogenization buffer 
(see Note 2).
 3. Add 4× volume homogenization buffer to the sample (e.g., 
30 mg sample and 120 μL buffer).
 4. Homogenize the mixture by Pellet Pestle Motor for 3 × 10 s 
(see Note 3).
 5. Centrifuge the homogenate at 4 °C for 10 min at 10,000 × g, 
and collect the supernatant, and store at −80 °C for maximum 
1 month.
 6. Measure protein concentration by a BCA kit. Usually 20× dilu-
tion of tissue homogenates is required.
 1. In case of perfusate sample, use Amicon Ultra 30 kDa concen-
trating tubes to concentrate 4 × 3 mL perfusate sample to 
50–100 μL.
 2. Pour 3 mL perfusate in the concentrating insert of an Amicon 
tube.
 3. Put concentrating insert into the tube and close it. Spin sam-
ples at 7500 × g for 20 min, 4 °C.
 4. Remove the concentrating insert and discard the flow-through 
from the tube. Reinsert the concentrating insert.
 5. Pour 3 mL perfusate in the insert, recap, and spin it for 20 min. 
Repeat steps 3–4 twice more.
 6. Pipette out the concentrated sample from the insert into an 
Eppendorf tube.
 7. Measure protein concentration by BCA kit. Usually 3× dilu-
tion of perfusate concentrates is required.
 1. For cell culturing see Ref. 31 (culturing neonatal cardiac 
myocytes).
 2. Remove treating solutions and wash cells in 2 mL PBS two 
times and then remove PBS.
 3. Scrape cells from two wells of a 6-well plate in 200 μL zymog-
raphy homogenization buffer (two wells together are 400 μL 
and they are collected into one tube after washing both wells). 
In case of 25 cm2 flask use 400 μL buffer; in case of 75 cm2 
flask, use 1 mL buffer.
 4. Keep Eppendorf tubes with the suspensions on ice and take 
into −80 °C freezer or concentrate them freshly.
3.1 Sample 
Preparation
3.1.1 Pulverized 
Tissue Sample
3.1.2 Preparing 
Perfusate Samples
3.1.3 Cell Culture 
Lysates
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 1. Keep samples on ice.
 2. Homogenize the mixture by ultrasonic homogenizer 2× 5 s on 
ice.
 3. Centrifuge cell homogenates at 5000 × g for 10 min at 4 °C.
 4. Collect supernatant.
 5. Centrifuge the supernatant in Amicon Ultra 10 kDa concen-
trating tubes to increase the sample protein concentration 
(4000 × g for 30–50 min at −4 °C).
 6. Put 50–100 μL samples into −80 °C freezer in two aliquots 
(one aliquot for determination of protein concentration).
 7. Measure protein concentration by BCA kit. Usually 3× dilu-
tion of cell concentrates is required.
 1. Assemble electrophoresis unit (see Note 4).
 2. Insert a comb between the gel-casting glasses and mark desired 
level of separating gel on the front glass (at the bottom of the 
teeth of the comb).
 3. Mix 30% acrylamide/0.8% bisacrylamide solution with Tris–
HCl pH 8.8, gelatin solution, and ddH2O (Table 2; see Notes 
5 and 6).
 4. Add 10% APS solution and TEMED to the mix quickly 
(Table 2).
3.2 Concentration 
of Samples
3.3 Preparation 
of Separating Gel
Table 2 
Preparation of separating gel between 0.75–1.5 mm thickness
Stock solutionsa
Final acrylamide concentration in the separating gel (%)
7.0 7.5
8.0
9.0 10.0
Small gel 
(15 mL)
Large gel 
(22.5 mL)
30% acrylamide/0.8% 
bisacrylamide (mL)
3.5 3.75 4.0 6 4.5 5.0
1.5 M Tris–HCl, pH 8.8 (mL) 3.75 3.75 3.75 5.62 3.75 3.75
ddH2O (mL) 6.25 6.0 5.75 8.62 5.25 4.75
Gelatin/casein/elastin solution
(20/20/12 mg/mL, 1% w/v 
SDS; mL)
1.5 1.5 1.5 2.25 1.5 1.5
10% w/v Ammonium Persulfate 
Solution (APS; μL)
50 50 10 75 50 50
TEMED (μL) 10 10 10 15 10 10
aSee Notes 8 and 9
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 5. Swirl to get homogenous gel. Avoid bubbling. Use immedi-
ately as polymerization process has begun (see Note 7).
 6. Using a pipette, pour a small amount into sandwich plates and 
watch for leakage. In the absence of leakage, continue filling 
up to 1 mm above line.
 7. Gently add butanol (with a 27G-needle connected to a 
10-mL syringe) along the surface of the gel to remove bub-
bles (see Note 8).
 8. Allow gel to polymerize (approximately 20 min at 25 °C; see 
Note 9). Use this time to prepare stacking gel (without adding 
TEMED and 10% APS).
 9. A layer of H2O on the surface of the gel will be visible when 
polymerization is completed. Drain this layer from the unit 
with a small stripe of blotting/filter paper.
 1. Mix 30% acrylamide/0.8% bisacrylamide solution with Tris–
HCl, pH 6.8 and ddH2O (Table 3).
 2. Add 10% SDS, 10% APS, and TEMED quickly (Table 3).
 3. Swirl to mix. Avoid bubbling. Use immediately as polymeriza-
tion process has begun.
 4. Place comb in units and then use pipettes to pour stacking gel.
 5. Allow gels to polymerize (approximately 15 min at 25 °C). 
Use this time to make sample calculation.
 1. According to the results of protein measurement, sample load-
ing mass and volume should be calculated.
 2. From a tissue homogenate, 50 μg protein per lane should be 
loaded. Since we load 15 μL per lane, this means that the final 
protein concentration of sample needs to be 50 μg/15 μL.
 3. In case you want to load a sample only once, it is enough to 
prepare 2× volume of one load (30 μL), which means that we 
3.4 Preparation 
of Stacking Gel
3.5 Sample 
Calculation
Table 3 
Preparation of 5 mL stacking gel
Stock solutions Volume
30% acrylamide/0.8% bisacrylamide 1 mL
0.5 M Tris–HCl pH 6.8 1.25 mL
ddH2O 3.05 mL
10% SDS 50 μL
10% w/v Ammonium Persulfate Solution (APS) 25 μL
TEMED 8 μL
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should add 6 μL (1/5 part) “pink” or 20 μL (2/3 part) “blue” 
loading buffer.
 4. The remaining 24 or 10 μL, respectively, should contain 
2 × 50 μg = 100 μg protein. Therefore, volume of the sample 
will be: V1 = 100 μg/protein concentration of your sample.
 5. Then we should add ddH2O to dilute samples. The required 
volume of ddH2O is: V2 = 30 − V1.
Taken together:
Loading volume: 15 μL
Loaded protein: 50 μg
Prepared volume: 30 μL (2× loading volume)
Prepared (sample) 
mass:
2× loaded protein (100 μg)
“Pink” loading 
buffer:
1/5 of prepared volume (6 μL) OR
“Blue” loading 
buffer:
2/3 of prepared volume (20 μL)
Sample volume: V1 = 2× loaded protein (2× 50 μg)/
sample protein concentration (μg/μL)
ddH2O: V2 = Prepared volume (30 μL) − V1
 1. Prepare and cool down ELFO buffer: 50 mL ELFO + 450 mL 
ddH2O (avoid bubbles, mix it gently) (see Note 10).
 2. Mark gel lanes for sample loading. Do not use the two outside 
lanes.
 3. When gel is polymerized, remove combs by pulling it straight 
up.
 4. Remove gel plates and snap onto electrode assembly 
(see Note 11).
 5. Fill up the lower and the upper buffer container with tank 
buffer.
 6. In case of casein zymography: pre-run electrophoresis at 
40 mV for 15 min at 4 °C before the samples are loaded into 
the wells. Another possibility is to load sample buffer into one 
well and pre-run electrophoresis at 4 °C until it reaches the 
bottom of the gel. Afterwards continue with step 7, but keep 
gels at 4 °C (see Note 12).
 7. Load samples
For identification of different isoforms of detected MMPs, 
positive controls (e.g., zymography standard containing 
3.6 Sample Loading 
and Running Gels
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human MMP-2 and -9 or MMP-2 standard) should be used. 
Page ruler is also useful to detect the different size of bands. 
Leave at least one lane loaded with sample(s) for negative con-
trol (see in Subheading 3.6).
 8. Connect electrodes properly (red to red, black to black) and 
set to 90 V.
 9. Let the samples run until loading buffer (running front) 
reaches the bottom of the gel (see Note 13).
 10. Use this time to prepare renaturation and development 
buffers.
 1. Set dry incubator at 37 °C.
 2. Disassemble the casting apparatus.
 3. Cut down lanes for negative control (see Note 14).
 4. Wash gels for 40 min in 200 mL renaturation buffer between 
20–25 °C (see Notes 15 and 16).
 5. Place gels into 200 mL freshly prepared development buffer (see 
Note 16). For negative control, incubate lane(s) separately in 
development buffer substituted with 10 mM EGTA solution.
 6. Incubate gels in dry incubator at 37 °C for 20–40 h (see Note 17).
 1. Immerse gels into 0.05–0.1% Coomassie Brilliant Blue solu-
tion. Place on a shaker for 1 h (see Note 18).
 2. Incubate gels in destaining solution and place on a shaker (at 
least for 60 min; see Notes 19 and 20).
 3. Gelatinolytic activities should be detected as transparent bands 
against the blue background of Coomassie Brilliant Blue-
stained gelatin (see Figs. 1–3).
 4. Scan the gel in transilluminator mode with a special gel scanner 
or gel-documentation system.
 5. Evaluate MMPs activity by using a gel/film evaluation soft-
ware (e.g., Quantity one, Bio-Rad).
The present description provides details for performing in situ 
zymography for MMP-2 in cardiac myocytes (Fig. 3); however, 
techniques for showing other MMP activities in different tissue 
sections or cell cultures in situ also exist and a description for gen-
eral in situ zymography is available in Ref. 32.
 1. Culture neonatal rat cardiac myocytes [31] or other cell types 
in 24-well tissue culture plate at the density of 105 cells/well 
for 3 days.
 2. Replace the growth medium (DMEM—Dulbecco’s Modified 
Eagle Medium—supplemented with Glu, AB/AM, 1% FBS) 
3.7 Washing 
and Incubating Gels
3.8 Staining Gels 
and Preparation 
for Evaluation of MMP 
Activity
3.9 In Situ 
Zymography
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with a “stress” solution containing DQ substrate at 40 μg/mL 
concentration. In case of control group, replace the medium of 
the cells with a control solution containing DQ substrate at the 
abovementioned concentration.
 3. Subject cells to circumstances according to your aim/project, 
which may induce intracellular MMP-2 activation.
 4. For negative control samples, use ilomastat (at 0.5 μM final 
concentration), or other non-specific MMP inhibitor (e.g., 
1,10-phenanthroline, between 1 and 5 mM final concentra-
tion, SB-3CT between 1 and 10 nM final concentration).
 5. Subsequently, replace “stress” solution with growth medium 
containing DQ substrate at 40 μg/mL concentration (250 μL 
volume must be applied onto the cells).
 6. Replace the medium, and wash cells twice with 
Dulbecco’s-PBS.
 7. Rinse cells in 3.7% paraformaldehyde in PBS between 20–25 °C 
for 15 min.
 8. Wash cells twice with PBS.
 9. Rinse coverslips with mounting medium and view fluorescent 
signal under fluorescent microscope.
 10. If it is necessary, you can combine in situ zymography with 
immunocytochemistry. In this case, after the fixation you 
should continue with an appropriate immunostaining 
protocol.
4 Notes
 1. Gelatin is very sensible. Make sure that gelatin dissolves com-
pletely (clear, transparent solution without any opalescent par-
ticle). Avoid gelatinization: prolonged cooling leads to gel 
formation. When SDS is added, avoid precipitation. If gelatin 
precipitates, try to heat again. If precipitates do not disappear 
from the solution, prepare a new gelatin solution. Precipitated 
gelatin does not polymerize homogenously in the gel, which 
may lead to equivocal results.
 2. Avoid reducing agents (e.g., dithiothreitol; DTT) or protease 
inhibitors (e.g., phenylmethanesulfonyl fluoride; PMSF) in the 
homogenization buffer. They may reduce or inhibit MMP 
activities, thereby may lead to false results.
 3. Avoid ultrasonic homogenizer. It can destroy the native struc-
ture of MMPs; therefore, enzymes may lose their activities.
 4. 7.5–10% polyacrylamide gels are recommended for gelatin 
zymography. For casein zymography, we recommend to use 
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10–15% gels according to the MW of active MMP-7 (19–
21 kDa; 28–30 kDa pro-MMP-7).
 5. Mix 15.0 mL of separating gel. This volume is sufficient for 1 
small unit (containing ten lanes; i.e., two gels), or mix 22.5 mL 
for a triple-wide unit (containing 30–34 lanes).
 6. In order to avoid leakage, ensure that spacers, comb, and glass 
plates are aligned properly.
 7. Make sure that gel is horizontal and there is no difference in 
the levels of the two edges.
 8. Avoid “shooting” of butanol. Butanol should cover the whole 
surface of the gel uniformly.
 9. TIP: leave pipette tip in the remnant of separating gel; when it 
is polymerized, you will be able to lift it with the pipette.
 10. Calculate the necessary volume of ELFO buffer according to 
the buffer tank.
 11. Eliminate bubbles under the gel, they may disturb gel 
running.
 12. Casein migrates in gel during electrophoresis. Due to its low 
molecular weight (23 kDa), the zone containing casein can 
obscure MMP-7 (latent form: 29 kDa, active form: 20 kDa) 
after staining. Therefore, pre-run of casein-embedded gel is 
recommended before classical zymogram procedure in order 
to get excess of casein out of the gel. The amount of remaining 
casein is sufficient for detection of MMP activities [33].
 13. Average time for gel running: 1.5–2 h.
 14. Avoid gel rupture. Cut the different corner of the gels to be 
able to identify the gels later (e.g., cut the bottom left corner 
of gel #1, and both the top and bottom left corners for gel #2). 
(Ensure that the gel is oriented correctly so that you don’t 
accidentally cut the right side corner.)
 15. Before preparation of renaturation and development buffers, 
make sure that the buffers do not contain any visible contami-
nation (e.g., fungal particles). Buffers should be clear and 
transparent.
 16. Make sure that gels immerse in the buffers and are not attached 
to the wall of the dish.
 17. Even before staining, gelatinolytic activity can be visible. Hold 
the gel up against a dark background to visualize it, if not, 
longer incubation should be applied. A pilot zymography is 
recommended to run for setting up the optimal incubation 
time. For example, 20-h incubation is recommended in case of 
human plasma, rat heart, and rodent lung samples, while 40-h 
incubation is required for mouse heart samples.
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 18. Staining can be longer, if it is necessary. The gel should be dark 
blue, protein ladder should be invisible.
 19. Use clear dish and change destaining solution after 5–10 min, 
if it becomes bluish.
 20. Leave the gel in destaining solution until the stacking gel 
becomes completely destained (transparent) again (see Figs. 1 
and 3). It can last even for 12 h.
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